The objective of this collated research paper is to highlight the anti-diabetic effects and mode of action of imeglimin, the first in a new tetrahydrotriazine-containing class of oral anti-diabetic agents: the glimins. Imeglimin acts on both insulin resistant organs (liver and muscle) and pancreatic -cells (insulin secretion in response to glucose and protection against apoptosis).
No takes yet. Share an insight, caveat, or question.
Fouqueray et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: